Stock IMNM IMMUNOME, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Immunome, Inc.

Equities

IMNM

US45257U1088

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-05-31 pm EDT 		5-day change 1st Jan Change
14.94 USD +1.36% Intraday chart for Immunome, Inc. +5.06% +39.63%
May. 31 Piper Sandler Initiates Immunome With Overweight Rating, $27 Price Target MT
May. 21 Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing MT

Evolution of the average Target Price on Immunome, Inc.

Price target over the last 5 years

History of analyst recommendation changes

c1928529a.yDhxUm2VFXkoi0ck4PbH2qP5hTXh8g3dXqbafprgyQk.jUo9GSWkeytD6iVov4a2mO6XxGy4tjjsEpKCTK6Zi2ifYjwqBeJEEh_qDg~8602f072145708380e46677dae01e2b1

Analyst Recommendations on Immunome, Inc.

Piper Sandler Initiates Immunome With Overweight Rating, $27 Price Target MT
Immunome Insider Bought Shares Worth $1,388,072, According to a Recent SEC Filing MT
JPMorgan Starts Immunome With Overweight Rating, $24 Price Target MT
Guggenheim Starts Immunome With Buy Rating, $35 Price Target MT
Wedbush Adjusts Immunome's Price Target to $33 From $27, Maintains Outperform Rating MT
Wedbush Raises Immunome's PT to $27 From $19 on Heels of Announced Plans to Acquire AL101, AL102 From Ayala Pharmaceuticals; Keeps Outperform Rating MT
Wedbush Raises Immunome's PT to $19 From $12 After Acquiring IM-1021 From Zentalis Pharmaceuticals, Maintains Outperform Rating MT
Immunome Shares Rise After Wedbush Starts Coverage With outperform Rating MT
Wedbush Starts Immunome With Outperform Rating, $12 Price Target; Has Positive View for Early-Stage Pipeline of Targeted Cancer Therapies MT
Chardan Cuts Price Target on Immunome to $8 From $9, Maintains Buy Rating MT
Cantor Fitzgerald Initiates Immunome's Coverage With Overweight Rating, Sets Price Target at $8 MT
Chardan Adjusts Immunome's Price Target to $9 From $16, Citing IMM-BCP-01 Launch Expectations, Stock Dilution From Future Capital Raises; Buy Rating Kept MT
Cantor Fitzgerald Starts Immunome at Overweight with $35 Price Target MT
IMMUNOME : Chardan Adjusts Price Target on Immunome to $21 From $18 on Q2 Update, Maintains Buy Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
14.94 USD
Average target price
32.5 USD
Spread / Average Target
+117.54%
High Price Target
38 USD
Spread / Highest target
+154.35%
Low Price Target
24 USD
Spread / Lowest Target
+60.64%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Immunome, Inc.

Piper Sandler
JPMorgan Chase
Guggenheim
Wedbush
Chardan Research
Cantor Fitzgerald
Chardan

Ratings for Immunome, Inc.

Trading Rating
Investor Rating
ESG Refinitiv
D+
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. IMNM Stock
  4. Consensus Immunome, Inc.